A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630) (NCT03833167)
KEYNOTE-630
This trial is No longer recruiting
Registration number NCT03833167
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mitchell Chipman
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR